메뉴 건너뛰기




Volumn 364, Issue , 2019, Pages

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: Prospective cohort study

(16)  Gottenberg, Jacques Eric a,b   Morel, Jacques c   Perrodeau, Elodie d   Bardin, Thomas e   Combe, Bernard c   Dougados, Maxime f   Flipo, Rene Marc g   Saraux, Alain h   Schaeverbeke, Thierry i   Sibilia, Jean a   Soubrier, Martin j   Vittecoq, Olivier k   Baron, Gabriel d   Constantin, Arnaud l   Ravaud, Philippe d   Mariette, Xavier m  


Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; NEW DRUG; PREDNISONE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

EID: 85060527591     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.l67     Document Type: Article
Times cited : (99)

References (28)
  • 1
    • 77957196913 scopus 로고    scopus 로고
    • Rheumatoid arthritis
    • Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010;376:1094-108. doi:10.1016/S0140-6736(10)60826-4
    • (2010) Lancet , vol.376 , pp. 1094-1108
    • Scott, D.L.1    Wolfe, F.2    Huizinga, T.W.3
  • 2
    • 33846239331 scopus 로고    scopus 로고
    • Silman AJBritish Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: Results from a large UK national cohort study
    • Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJBritish Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20. doi:10.1002/art.22331
    • (2007) Arthritis Rheum , vol.56 , pp. 13-20
    • Hyrich, K.L.1    Lunt, M.2    Watson, K.D.3    Symmons, D.P.4
  • 3
    • 33746961890 scopus 로고    scopus 로고
    • Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    • REFLEX Trial Group
    • Cohen SB, Emery P, Greenwald MW, et al, REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. doi:10.1002/art.22025
    • (2006) Arthritis Rheum , vol.54 , pp. 2793-2806
    • Cohen, S.B.1    Emery, P.2    Greenwald, M.W.3
  • 4
    • 52149099504 scopus 로고    scopus 로고
    • IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: Results from a 24-week multicentre randomised placebocontrolled trial
    • Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebocontrolled trial. Ann Rheum Dis 2008;67:1516-23. doi:10.1136/ard.2008.092932
    • (2008) Ann Rheum Dis , vol.67 , pp. 1516-1523
    • Emery, P.1    Keystone, E.2    Tony, H.P.3
  • 5
    • 24944498854 scopus 로고    scopus 로고
    • Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition
    • Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23. doi:10.1056/NEJMoa050524
    • (2005) N Engl J Med , vol.353 , pp. 1114-1123
    • Genovese, M.C.1    Becker, J.C.2    Schiff, M.3
  • 6
    • 78751704593 scopus 로고    scopus 로고
    • Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: A meta-analysis
    • Salliot C, Finckh A, Katchamart W, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011;70:266-71. doi:10.1136/ard.2010.132134
    • (2011) Ann Rheum Dis , vol.70 , pp. 266-271
    • Salliot, C.1    Finckh, A.2    Katchamart, W.3
  • 7
    • 84863846460 scopus 로고    scopus 로고
    • Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: Systematic review and indirect pairwise meta-analysis
    • Schoels M, Aletaha D, Smolen JS, Wong JB.comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012;71:1303-8. doi:10.1136/annrheumdis-2011-200490
    • (2012) Ann Rheum Dis , vol.71 , pp. 1303-1308
    • Schoels, M.1    Aletaha, D.2    Smolen, J.S.3    Wong, J.B.4
  • 8
    • 77953122551 scopus 로고    scopus 로고
    • Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs
    • Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2010;39:425-41. doi:10.1016/j.semarthrit.2009.12.002
    • (2010) Semin Arthritis Rheum , vol.39 , pp. 425-441
    • Bergman, G.J.1    Hochberg, M.C.2    Boers, M.3    Wintfeld, N.4    Kielhorn, A.5    Jansen, J.P.6
  • 9
    • 74849094402 scopus 로고    scopus 로고
    • Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
    • All Departments of Rheumatology in Denmark
    • Hetland ML, Christensen IJ, Tarp U, et al, All Departments of Rheumatology in Denmark. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32. doi:10.1002/art.27227
    • (2010) Arthritis Rheum , vol.62 , pp. 22-32
    • Hetland, M.L.1    Christensen, I.J.2    Tarp, U.3
  • 10
    • 79951697104 scopus 로고    scopus 로고
    • Registries in rheumatoid arthritis and autoimmune diseases: Data from the French registries
    • Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology (Oxford) 2011;50:222-9. doi:10.1093/rheumatology/keq368
    • (2011) Rheumatology (Oxford) , vol.50 , pp. 222-229
    • Mariette, X.1    Gottenberg, J.E.2    Ravaud, P.3    Combe, B.4
  • 11
    • 84964378350 scopus 로고    scopus 로고
    • Using big data to emulate a target trial when a randomized trial is not available
    • Hernan MA, Robins JM. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available. Am J Epidemiol 2016;183:758-64. doi:10.1093/aje/kwv254
    • (2016) Am J Epidemiol , vol.183 , pp. 758-764
    • Hernan, M.A.1    Robins, J.M.2
  • 12
    • 0000157861 scopus 로고
    • Model-based direct adjustment
    • Rosenbaum PR. Model-based direct adjustment. J Am Stat Assoc 1987;82:387-94. doi:10.1080/01621459.1987.10478441
    • (1987) J Am Stat Assoc , vol.82 , pp. 387-394
    • Rosenbaum, P.R.1
  • 13
    • 0033847784 scopus 로고    scopus 로고
    • Marginal structural models and causal inference in epidemiology
    • Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-60. doi:10.1097/00001648-200009000-00011
    • (2000) Epidemiology , vol.11 , pp. 550-560
    • Robins, J.M.1    Hernan, M.A.2    Brumback, B.3
  • 14
    • 84944796673 scopus 로고    scopus 로고
    • Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
    • Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015;34:3661-79. doi:10.1002/sim.6607
    • (2015) Stat Med , vol.34 , pp. 3661-3679
    • Austin, P.C.1    Stuart, E.A.2
  • 15
    • 70449647008 scopus 로고
    • Proportional hazards tests and diagnostics based on weighted residuals
    • Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1994;81:515-62. doi:10.1093/biomet/81.3.515
    • (1994) Biometrika , vol.81 , pp. 515-526
    • Grambsch, P.M.1    Therneau, T.M.2
  • 16
    • 80955180013 scopus 로고    scopus 로고
    • The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt
    • Royston P, Parmar MK. The use of restricted mean survival time to estimate the treatment effect in randomized clinical trials when the proportional hazards assumption is in doubt. Stat Med 2011;30:2409-21. doi:10.1002/sim.4274
    • (2011) Stat Med , vol.30 , pp. 2409-2421
    • Royston, P.1    Parmar, M.K.2
  • 17
    • 85019652334 scopus 로고    scopus 로고
    • Life expectancy difference and life expectancy ratio: Two measures of treatment effects in randomised trials with non-proportional hazards
    • Dehbi HM, Royston P, Hackshaw A. Life expectancy difference and life expectancy ratio: two measures of treatment effects in randomised trials with non-proportional hazards. BMJ 2017;357:j2250. doi:10.1136/bmj.j2250
    • (2017) BMJ , vol.357 , pp. j2250
    • Dehbi, H.M.1    Royston, P.2    Hackshaw, A.3
  • 18
    • 84961718582 scopus 로고    scopus 로고
    • Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: Results from a multicentre study
    • Pascart T, Philippe P, Drumez E, et al.comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study. Int J Rheum Dis 2016;19:1093-102. doi:10.1111/1756-185X.12845
    • (2016) Int J Rheum Dis , vol.19 , pp. 1093-1102
    • Pascart, T.1    Philippe, P.2    Drumez, E.3
  • 19
    • 79957630321 scopus 로고    scopus 로고
    • All departments of rheumatology in Denmark. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: Results from the nationwide Danish DANBIO registry
    • Leffers HC, Ostergaard M, Glintborg B, et al, all departments of rheumatology in Denmark. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis 2011;70:1216-22. doi:10.1136/ard.2010.140129
    • (2011) Ann Rheum Dis , vol.70 , pp. 1216-1222
    • Leffers, H.C.1    Ostergaard, M.2    Glintborg, B.3
  • 20
    • 84898016179 scopus 로고    scopus 로고
    • Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy
    • Das S, Vital EM, Horton S, et al. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Ann Rheum Dis 2014;73:909-12. doi:10.1136/annrheumdis-2013-204417
    • (2014) Ann Rheum Dis , vol.73 , pp. 909-912
    • Das, S.1    Vital, E.M.2    Horton, S.3
  • 21
    • 84961950220 scopus 로고    scopus 로고
    • Rituximab done: What's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis
    • Walker UA, Jaeger VK, Chatzidionysiou K, et al, Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. Rheumatology (Oxford) 2016;55:230-6. doi:10.1093/rheumatology/kev297
    • (2016) Rheumatology (Oxford) , vol.55 , pp. 230-236
    • Walker, U.A.1    Jaeger, V.K.2    Chatzidionysiou, K.3
  • 22
    • 84999780389 scopus 로고    scopus 로고
    • Comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry
    • Harrold LR, Reed GW, Solomon DH, et al.comparative effectiveness of abatacept versus tocilizumab in rheumatoid arthritis patients with prior TNFi exposure in the US Corrona registry. Arthritis Res Ther 2016;18:280. doi:10.1186/s13075-016-1179-7
    • (2016) Arthritis Res Ther , vol.18 , pp. 280
    • Harrold, L.R.1    Reed, G.W.2    Solomon, D.H.3
  • 23
    • 84971299229 scopus 로고    scopus 로고
    • Brief report: Association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: Results from the pan-european registry analysis
    • Gottenberg JE, Courvoisier DS, Hernandez MV, et al. Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis. Arthritis Rheumatol 2016;68:1346-52. doi:10.1002/art.39595
    • (2016) Arthritis Rheumatol , vol.68 , pp. 1346-1352
    • Gottenberg, J.E.1    Courvoisier, D.S.2    Hernandez, M.V.3
  • 24
    • 84877275257 scopus 로고    scopus 로고
    • Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): A randomised, double-blind, controlled phase. 4 trial
    • ADACTA Study Investigators
    • Gabay C, Emery P, van Vollenhoven R, et al, ADACTA Study Investigators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase. 4 trial. Lancet 2013;381:1541-50. doi:10.1016/S0140-6736(13)60250-0
    • (2013) Lancet , vol.381 , pp. 1541-1550
    • Gabay, C.1    Emery, P.2    Van Vollenhoven, R.3
  • 25
    • 84889641417 scopus 로고    scopus 로고
    • Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Two-year efficacy and safety findings from AMPLE trial
    • Schiff M, Weinblatt ME, Valente R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 2014;73:86-94. doi:10.1136/annrheumdis-2013-203843
    • (2014) Ann Rheum Dis , vol.73 , pp. 86-94
    • Schiff, M.1    Weinblatt, M.E.2    Valente, R.3
  • 26
    • 85045006911 scopus 로고    scopus 로고
    • The C-word: Scientific euphemisms do not improve causal inference from observational data
    • Hernan MA. The C-Word: Scientific Euphemisms Do Not Improve Causal Inference From Observational Data. Am J Public Health 2018;108:616-9. doi:10.2105/AJPH.2018.304337
    • (2018) Am J Public Health , vol.108 , pp. 616-619
    • Hernan, M.A.1
  • 27
    • 84867401801 scopus 로고    scopus 로고
    • Positivity for anticyclic citrullinated peptide is associated with a better response to abatacept: Data from the 'Orencia and Rheumatoid Arthritis' registry
    • Gottenberg JE, Ravaud P, Cantagrel A, et al. Positivity for anticyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry. Ann Rheum Dis 2012;71:1815-9. doi:10.1136/annrheumdis-2011-201109
    • (2012) Ann Rheum Dis , vol.71 , pp. 1815-1819
    • Gottenberg, J.E.1    Ravaud, P.2    Cantagrel, A.3
  • 28
    • 77956391149 scopus 로고    scopus 로고
    • AutoImmunity and Rituximab registry and French Society of Rheumatology. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry
    • Gottenberg JE, Ravaud P, Bardin T, et al, AutoImmunity and Rituximab registry and French Society of Rheumatology. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010;62:2625-32. doi:10.1002/art.27555
    • (2010) Arthritis Rheum , vol.62 , pp. 2625-2632
    • Gottenberg, J.E.1    Ravaud, P.2    Bardin, T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.